Alpha 2.0
Login Register
» Articles » PMID: 21562851

Tetramethylpyrazine Reverses Multidrug Resistance in Breast Cancer Cells Through Regulating the Expression and Function of P-glycoprotein

Overview
Journal Med Oncol
Publisher Springer
Specialty Oncology
Date 2011 May 13
PMID 21562851
Citations 23
Authors
Yinxu Zhang
Xiaomei Liu
Teng Zuo
Yu Liu
Jun Hua Zhang
Affiliations
Soon will be listed here.
Abstract

Tumor multidrug resistance (MDR) has become the major obstacle to cancer chemotherapy. Recent studies suggest that tetramethylpyrazine (TMP) could reverse tumor MDR although the mechanism by which TMP overcomes tumor MDR remains elusive. Therefore, in this study, we examined the effects of TMP on MDR in drug-resistant breast cancer cells and investigated the underlying mechanisms. MCF-7 cells and the derived P-glycoprotein (Pgp) overexpressing MCF-7/dox cells were treated with TMP, and their growth was examined by MTT assay. Doxorubicin accumulation in the cells was evaluated by flow cytometry, and the expression of Pgp was detected by Western blot and RT-PCR analysis. The results showed that TMP increased the intracellular concentration of doxorubicin and inhibited Pgp-mediated efflux of doxorubicin in a dose-dependent manner. Moreover, TMP inhibited the ATPase activity of P-gp and suppressed the expression of Pgp in MCF-7/dox cells. Taken together, these data suggest that TMP has potential application in the treatment of chemotherapy-resistant breast cancer.

Citing Articles

Tetramethylpyrazine Inhibits the Proliferation and Invasion of Glioma Cells by Regulating the UBL7-AS1/miR-144-3p Pathway.

Liang R, Zhang G, Xu W, Liu W, Tang Y Evid Based Complement Alternat Med. 2022; 2022:5261285.

PMID: 36045665 PMC: 9423964. DOI: 10.1155/2022/5261285.

Tetramethylpyrazine: A Review of Its Antitumor Potential and Mechanisms.

Yang S, Wu S, Dai W, Pang L, Xie Y, Ren T Front Pharmacol. 2022; 12:764331.

PMID: 34975475 PMC: 8716857. DOI: 10.3389/fphar.2021.764331.

New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer.

An J, Peng C, Tang H, Liu X, Peng F Int J Mol Sci. 2021; 22(17).

PMID: 34502549 PMC: 8431789. DOI: 10.3390/ijms22179644.

Phytochemicals: Potential Lead Molecules for MDR Reversal.

Tinoush B, Shirdel I, Wink M Front Pharmacol. 2020; 11:832.

PMID: 32636741 PMC: 7317022. DOI: 10.3389/fphar.2020.00832.

Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.

Liu Y, Yan Z, Xia Y, Xie X, Zhou K, Xu L Am J Cancer Res. 2020; 10(3):939-952.

PMID: 32266101 PMC: 7136924.

References
1.
Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View
2.
Nobili S, Landini I, Giglioni B, Mini E . Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets. 2006; 7(7):861-79. DOI: 10.2174/138945006777709593. View
3.
Wang X, Wang S, Zhang Q, Liu M, Li H, Liu Y . Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep. 2009; 23(1):211-5. View
4.
Zhou C, Shen P, Cheng Y . Quantitative study of the drug efflux kinetics from sensitive and MDR human breast cancer cells. Biochim Biophys Acta. 2007; 1770(7):1011-20. DOI: 10.1016/j.bbagen.2007.02.011. View
5.
Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View